Moritz Rau

Moritz Rau

Auto-generated profile, based on publicly available information

Moritz Rau

Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany; German Center for Mental Health (DZPG), Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBSara De Biasi
Sara De Biasi
DTDomenico Lo Tartaro
Domenico Lo Tartaro
ANAnita Neroni
Anita Neroni
MRMoritz Rau
Moritz Rau
NPNikolaos Paschalidis
Nikolaos Paschalidis
ACAndrea Cossarizza
Andrea Cossarizza
Disease-modifying therapies (DMT) administered to patients with multiple sclerosis (MS) can influence immune responses to SARS-CoV-2 and vaccine efficacy. However, data on the detailed phenotypic, functional and metabolic characteristics of antigen (Ag)-specific cells following the third dose of mRNA vaccine remain scarce. Here, using flow cytometry and 45-parameter mass cytometry, we broadly investigate the phenotype, function and the single-cell metabolic profile of SARS-CoV-2-specific T and B cells up to 8 months after the third dose of mRNA vaccine in a cohort of 94 patients with MS treated with different DMT, including cladribine, dimethyl fumarate, fingolimod, interferon, natalizumab, teriflunomide, rituximab or ocrelizumab. Almost all patients display functional immune response to SARS-CoV-2. Different metabolic profiles characterize antigen-specific-T and -B cell response in fingolimod- and natalizumab-treated patients, whose immune response differs from all the other MS treatments.


1 May 2026 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
MRMoritz Rau
Moritz Rau
LCLuise Victoria Claaß
Luise Victoria Claaß
LSLavinia Steinmann
Lavinia Steinmann
JHJulian Herpertz
Julian Herpertz
MRMaike Richter
Maike Richter
NONils Opel
Nils Opel

9 March 2026 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
JPJodie Painter
Jodie Painter
ARAlexander Refisch
Alexander Refisch
MRMoritz Rau
Moritz Rau
MWMartin Walter
Martin Walter
SMScott Mackey
Scott Mackey
NONils Opel
Nils Opel
Obesity is a highly prevalent metabolic risk factor that commonly coincides with additional metabolic, cardiovascular, and inflammatory abnormalities. Obesity has frequently been shown to affect brain physiology at multiple levels, and to increase the risk for the development of neuropsychiatric disorders such as major depression and dementia. Previous large-scale neuroimaging research has consistently shown overlapping brain structural alterations in obesity and neuropsychiatric disorders, with the most pronounced alterations being lower cortical thickness in the frontal and temporal cortex. Yet, the direction of association, and the potential causal effect of obesity on brain structural decline, remains unclear. Moreover, it is imperative to determine which of the multifaceted biological systems impacted by obesity, encompassing metabolic, cardiovascular, and inflammatory aspects, may be implicated in the link between obesity and brain structural decline. In this study, we employed univariate and multivariate Mendelian randomization (MR) as an instrumental variable (IV) approach to clarify the causal direction of the relationship between body mass index (BMI) and brain structure and to disentangle the metabolic, cardiovascular, and inflammatory factors that might underlie this relationship. We found evidence for a potential causal influence of elevated BMI on lower cortical thickness, with the most prominent effects in the precentral and fusiform gyrus. We furthermore found concurrent nominal associations of visceral adipose tissue (VAT) and the inflammatory serum marker CRP with lower cortical thickness which largely overlapped with regions associated with higher BMI. In contrast, very few associations with cortical thickness emerged for blood pressure or metabolic serum markers. Our findings thus corroborate the notion of a causal effect of BMI on lower cortical thickness. Future research should aim to delineate if and how the BMI related effect on brain structural decline conveys an increased risk for the development of neuropsychiatric disorders.